ENTRADA THERAPEUTICS
Entrada Therapeutics’ mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol. For more information, please visit www.entradatx.com.
ENTRADA THERAPEUTICS
Social Links:
Industry:
Biotechnology Emergency Medicine Genetics Health Care Medical
Founded:
2016-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.entradatx.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
175.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Global Site Tag
Similar Organizations
AmbAgon Therapeutics
AmbAgon Therapeutics is a developer of cancer molecule therapeutics.
Cognos Therapeutics
Cognos Therapeutics is a developer of diagnostic and drug delivery devices to detect diseases and deliver drugs.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Emedgene
Emedgene provides data-driven AI solutions for genomic diagnostics and discovery at scale.
EnteroBiotix
EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections.
Erasca
Erasca is a developer of oncology drugs intended to provide precision oncology options.
MiNDERA Corporation
MiNDERA Dx conducts research and development on non-invasive molecular testing for skin cancer and other skin diseases.
Neuron23
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Pyxis Oncology
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Spatial Genomics
Spatial Genomics is a developer of sequential fluorescence in situ hybridization (seqFISH) technology.
Vedanta Biosciences
Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.
Vico Therapeutics
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Wellington Management
Wellington Management investment in Series B - Entrada Therapeutics
TCG Crossover
TCG Crossover investment in Series B - Entrada Therapeutics
MRL Ventures Fund
MRL Ventures Fund investment in Series B - Entrada Therapeutics
MPM Capital
MPM Capital investment in Series B - Entrada Therapeutics
Greenspring Associates
Greenspring Associates investment in Series B - Entrada Therapeutics
CureDuchenne Ventures
CureDuchenne Ventures investment in Series B - Entrada Therapeutics
Redmile Group
Redmile Group investment in Series B - Entrada Therapeutics
Moore Strategic Ventures
Moore Strategic Ventures investment in Series B - Entrada Therapeutics
5AM Ventures
5AM Ventures investment in Series B - Entrada Therapeutics
Agent Capital
Agent Capital investment in Series B - Entrada Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-19 | Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer |
Official Site Inspections
http://www.entradatx.com Semrush global rank: 2.84 M Semrush visits lastest month: 5.7 K
- Host name: 165.227.248.71
- IP address: 165.227.248.71
- Location: Clifton United States
- Latitude: 40.8364
- Longitude: -74.1403
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07014
More informations about "Entrada Therapeutics"
Who We Are - Entrada Therapeutics
Entrada's mission is to treat devastating diseases with intracellular therapeutics.See details»
Entrada Therapeutics - LinkedIn
Headquartered in Boston’s Seaport community, Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines ...See details»
DREAMS Grant Program - Entrada Therapeutics
Learn more about our competitive grant program to advance diversity, equity, inclusion and accessibility.See details»
Entrada Therapeutics - Crunchbase Investor Profile
For more information, please visit www.entradatx.com. Read More. Lists Featuring This Company. Edit Lists Featuring This Company Section. East …See details»
Entrada Therapeutics | Entrada Therapeutics Appoints Gina …
Aug 10, 2023 Since joining CARGO in May of 2022, she has rapidly scaled the organization to advance its pipeline, executed on critical manufacturing milestones and successfully led her team to raise an upsized $200 million Series A financing. ... [email protected]. A photo accompanying this announcement is available at https://www.globenewswire.com ...See details»
Entrada Therapeutics | Entrada Therapeutics Awards Funding to …
The Akari Foundation is a non-profit organization dedicated to educating and empowering the Hispanic community about rare diseases, with a focus on Duchenne. Its mission is to provide resources, awareness, advocacy and education to affected families entirely in Spanish. ... The link you have selected will take you to a site outside Entradatx.com.See details»
Entrada Therapeutics Awards Funding to Non-Profit Organizations ...
Sep 7, 2023 The Akari Foundation is a non-profit organization dedicated to educating and empowering the Hispanic community about rare diseases, with a focus on Duchenne. ... [email protected] Patient ...See details»
Entrada Therapeutics: Culture | LinkedIn
Entrada is working to revolutionize the treatment of devastating diseases by engaging targets previously considered undruggable. Using our proprietary Endosomal Escape Vehicle (EEV™) platform ...See details»
Entrada Therapeutics to Present at Upcoming Investor Conferences
Live webcasts will be available on the Investor Relations section of the Company’s website at www.entradatx.com. Replays will be available on the Entrada website for 90 days following the events. About Entrada Therapeutics Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class ...See details»
Patients - Entrada Therapeutics
At its core, the role of patient advocacy at Entrada serves as a bridge between our colleagues and the patient communities we are here to help.See details»
Entrada Therapeutics Announces $100 Million Registered Direct …
Jun 24, 2024 – The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm –BOSTON, June 24, 2024 (GLOBE NEWSWIRE ...See details»
Entrada Therapeutics - Overview, News & Similar companies
Www.entradatx.com. Revenue $239.4 Million. Stock Symbol TRDA. Industry Business Services General Business Services . Most Recent Scoops. Jun 24 2024. Open Position. Jun 21 2024. Open Position. Entrada Therapeutics is currently seeking a Medical Director, Clinical Development. See all scoops. Highlights. $391M.See details»
Entrada Therapeutics Reports First Quarter 2024 Financial Results
For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including ...See details»
Facility Spotlight - Entrada Therapeutics
As you enter our office, we want you to get a feel for the cellular entry process.See details»
Entrada Therapeutics Promotes Nathan J. Dowden to President
Jan 3, 2024 Prior to Entrada, Nate served as Senior Vice President of Corporate Development at Rubius Therapeutics, where he supported the organization’s evolution from an early-stage discovery company into ...See details»
Entrada Therapeutics Strengthens Leadership Team with Key …
Dec 8, 2020 Company Contact: Nathan Dowden Entrada Therapeutics, Inc. [email protected] Investor Contact: Felicia Vonella W2O Group [email protected] Media Contact: Aulani Capuchin W2O Group (559) 355 ...See details»
Entrada Therapeutics | Investor Relations
Nov 5, 2024 The link you have selected will take you to a site outside Entradatx.com Entrada does not review or control the content of any non-Entrada site. Entrada does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Entrada sources.See details»
Entrada Therapeutics Promotes Nathan J. Dowden to President
Jan 3, 2024 Nathan J. Dowden President and Chief Operating Officer - With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help ...See details»
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
– Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – – On track to submit global regulatory filings for planned Phase 2 clinical trials for both E NTR-601-44 and ENTR-601-45See details»